edicinal preparations containing material or reaction products thereof with undetermined constitution (A61K35)

A61K35/02 - From inanimate materials(136)
A61K35/06 - ineral oils(32)
A61K35/08 - ineral waters(229)
A61K35/10 - Peat; amber(149)
A61K35/14 - Blood(661)
A61K35/16 - Plasma; serum(392)
A61K35/18 - Erythrocytes(81)
A61K35/20 - ilk; colostrum(118)
A61K35/22 - Urine; urinary system(16)
A61K35/23 - Kidney(8)
A61K35/26 - Lymph; lymph-glands; thymus(139)
A61K35/28 - arrow; spleen(240)
A61K35/30 - Nerves; brain(140)
A61K35/34 - uscles; heart(60)
A61K35/37 - Digestive system(11)
A61K35/38 - Stomach; intestine(46)
A61K35/39 - Pancreas(70)
A61K35/407 - (77)
A61K35/413 - (38)
A61K35/42 - Lungs(21)
A61K35/48 - Reproductive organs; embryos(186)
A61K35/50 - Placenta; amniotic fluid(195)
A61K35/52 - Sperm(16)
A61K35/54 - Ovary; eggs; embryos(114)
A61K35/62 - Leeches(78)
A61K35/64 - Insects, e.g. royal jelly(443)
A61K35/68 - Protozoa(12)
A61K35/70 - (65)
A61K35/72 - (41)
A61K35/74 - Bacteria(949)
A61K35/76 - Viruses(95)
A61K35/78 - (2848)
A61K35/80 - (89)
A61K35/82 - (8)
A61K35/84 - (15)

ethod for mammoplasty // 2628238
FIELD: medicine.SUBSTANCE: mammary gland (MG) plasty with high ptosis or a stretched "dermal sheath" is performed. At that, Botox is injected into the large pectoral muscle 8-10 days before the operation and into the cavity in the large pectoral muscle base during the operation, prior to implant insertion. During the operation, the MG skin within the operating field is shrunk by exposure to laser radiation or ultrasound. Fibrin glue mixed with a solution of a nonpolarizing muscle relaxant is used, and the cavity is washed with an antibiotic solution before drying.EFFECT: method has a high aesthetic effect, ensures the stability of the mammary gland with the necessary shape, minimizes ptosis, excludes scars on the incision site.3 cl, 14 dwg, 3 tbl, 3 ex
ethod for obtaining of msc-associated non-differentiated hemopoietic precursor cells with cd34+/cd133+ phenotype // 2628092
FIELD: biotechnology.SUBSTANCE: invention relates to production of cell cultures enriched with hematopoietic precursor cells with CD34+/CD133+ phenotype. The method includes preparation of a stromal sublayer, addition of an umbilical cord fraction, cultivation and selection. Multipotent stromal cells of adipose tissue (MSC) are obtained from the stromal-vascular fraction of adipose tissue, which are cultured at an O2 concentration of 5% in the environment. Mononuclear fraction of umbilical cord blood (MNF UB) is added to the MSC monolayer. After cocultivation, the undifferentiated hematopoietic precursors are selected from the mononuclear fraction of UB by adhesion to MSC at 20% O2, MSC is continued to be cultured with attached MNF UB for 96 hours at O2 concentration of 20% in the environment.EFFECT: invention allows to obtain a population enriched with undifferentiated hematopoietic umbilical cord blood precursors with this complex phenotype.9 dwg, 1 tbl, 1 ex

ethod of production of a combined antihelmint tablet with a symbiotic treatment for treatment of a small cattle // 2627893
FIELD: veterinary medicine.SUBSTANCE: invention is a method for producing a combined anthelmintic tablet with a symbiotic for treating small cattle containing a first and second layer comprising the steps of: adding a first powder mixture to a mould plate. Mentioned first powder mixture contains a pharmaceutically active substance and a binder, a second powder mixture is added to said mould plate. Mentioned second powder blend comprises a binder and the composition of mentioned second powder blend is different from the composition of mentioned first powder mixture, the first powder mixture and the second powder blend are pressed on said plate of the mould to form a tablet form and subjected to said tableted form with radio frequency emission for a period of Time sufficient to activate said binder within said tablet mould to fuse mentioned tableted Th form into said tablet, such that the density of mentioned tablet is less than about 0.8 g/cm3, characterized in that a bacterial concentrate is prepared for the preparation of the first powder mixture comprising a bifidobacterium adolescentis B-1 and Lactobacillus acidophilus LH-1 consortium with a titre of 108-1010 CFU/g sorbed on a carrier in a ratio of 1:1:12, which Is concentrated by filtration or centrifugation to a suspension containing 5 billion bacteria per ml, followed by mixing them in equal volumes. As the carrier, flour or bran is used at the rate of 12 parts of the support per part of a mixture of concentrated cultures, and then the obtained dry powder mass is mixed with lactulose, and to obtain the second powder mixture, ivermectin, praziquantel and at least one pharmaceutically acceptable excipient microcrystalline cellulose MCC is used, then the substances ivermectin, praziquantel and excipient are mixed in dry kind. The components in the tablet are in a certain ratio in wt %.EFFECT: invention provides high anthelmintic activity, intensification of treatment and prevention of a number of helminthic invasions, nonspecific correction of the immune response of the animal organism, normalization of hepatoprotective and reparative liver functions.6 ex, 1 tbl, 1 dwg
ethod for obtaining suspensional form of a ruled decellularized extracellular matrix // 2627844
FIELD: pharmacology.SUBSTANCE: method includes separating the cleaned extracellular matrix layers from the cleaned, extruding the layers, fractionating the powder and suspending the selected fraction of the purified extracellular matrix particles in a liquid medium by alternating the mixing and dispersing cycles of the particles in a liquid medium with a predominant mixing time at a temperature that does not induce denaturation of the collagen, and degassing the resulting particle suspension.EFFECT: method of the invention provides for the preparation of a suspension form of a decellularized extracellular matrix with an adjustable size of its structural components, the use of which allows for the injection of injections into the desired region without incision and easily filling the open wound defect of various tissues.12 cl, 6 dwg, 1 tbl
ethod for tubular bone defects plastic in patients with chronic osteomyelitis // 2627815
FIELD: medicine.SUBSTANCE: sanation of the osteomyelitis focus, plastic of the bone cavity by platelet-enriched autoplasm and biomaterial are performed. At that, prior to plastic surgery, a thin needle is rotated in various directions to provide revascularizing osteoperforation of the bone cavity walls along the edge of which the bioplastic membrane "Collost" is fixed with transossal sutures, without tightening the threads. The intact autologous muscle tissue is taken, which is ground to the state of muscle mince. It is mixed with the platelet-enriched autoplasma and densely placed in the bone cavity, which is sealed with the bioplastic membrane "Collost", tightening the threads of the transossal sutures.EFFECT: method allows to ensure sealing of the plastic area of tubular bones defects in patients with chronic osteomyelitis, to create optimal conditions for reparative processes of bone tissue.1 ex
ethod for chronic wounds treatment // 2627814
FIELD: medicine.SUBSTANCE: pre-sanitized wound is covered with a bioplastic membrane "Collost", fixing it with separate nodal sutures at a distance of 0.3 mm from each other. Near the upper edge of the wound, a subclavian catheter is installed, the tube of which is up to 1 mm and length is up to 150 mm . This tube is pre-perforated and inserted under the membrane through the upper edge of the wound. The membrane is covered with an antiseptic dressing so that the head with the subclavian catheter plug remains above it for daily single administration of platelet-enriched plasma, which is obtained by taking 20 ml of blood from the peripheral vein, which is centrifuged for 15 minutes at 4000 revolutions. Then, the liquid part of plasma is placed in a sterile tube without a stabiliser and is centrifuged at 3500 rpm for 15 minutes to obtain platelet-enriched plasma with a volume of up to 2 ml, which is injected through the subclavian catheter no later than 10 minutes after its production. The antiseptic bandage on the wound is replaced once in 5-7 days.EFFECT: method allows to increase the effectiveness of chronic wounds local treatment, reduce trauma, simplify wound treatment and care.1 ex
ethod for biofidobacterium metabolism products obtaining for treatment of combined radiation-thermal body damage and method for treatment of combined radiation-thermal body damage // 2627669
FIELD: medicine.SUBSTANCE: bifidobacteria are grown in 400-500 cm3 flasks with Blaurokk medium for 3-4 days in order to obtain products of their metabolism. The concentration of microbes is determined with standardization of their number to 1×108 CFU/cm. The bifidobacteria mixture with the products of their metabolism in the culture liquid is carefully shaken, poured into 50-100 cm3 centrifuge tube, centrifuged at 5000 rpm for 30 minutes. The resulting supernatant is decanted, the dry matter content is determined and adjusted to 10-15 mg/ml with physiological saline, sterilised by filtration, poured into bottles and stored in a refrigerator at a temperature of 4-6°C. Treatment of combined radiation-thermal body damage includes a 3-fold subcutaneous administration of the anti-ray serum of mammals mixed with metabolic products of bifidobacteria contained in the culture fluid obtained during the bifidobacteria growth in the ratio of 0.5:0.5 at a dose of 18.5-28 mg/kg in terms of protein, with an interval of 24, 48 and 168 hours after radiation-thermal trauma. Then, after 24, 48 and 168 hours, an ointment based on bee products and herbaceous oil is applied to the affected area.EFFECT: increased effectiveness of treatment of radiation-thermal body damage.2 cl, 4 tbl, 4 ex
Polybacterial drug with advantages for health: with antioxidant effect, decreased cholesterol concentration, anti-inflammatory and immuno-modulating effect, and release of bioactive peptides inhibiting angiotensin-converting enzyme // 2627651
FIELD: biotechnology.SUBSTANCE: group of inventions refers to polybacterial probiotic drug including new strains of lactic acid bacteria Lactobacillus gasseri 7/12 NBIMCC No. 8720, Lactobacillus plantarum F12 NBIMCC No. 8722 and Lactobacillus helveticus A1, NBIMCC No. 8721, which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity. The group of inventions also refers to the use of drug as a probiotic agent, as well as an agent which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity.EFFECT: food additives, food and functional products, pharmaceutical preparations that include this drug, have a beneficial effect on the health of people and animals.9 cl, 8 dwg, 15 tbl
Cosmetic means with mineral thermal water "dzhemukhskaya tselebnaya" // 2627619
FIELD: cosmetology.SUBSTANCE: cosmetic means for skin with mineral thermal water "Dzehmukhskaya tselebnaya", containing a thick licorice root extract dissolved in thermal water, silver sulfate, peppermint or lavender essential oil, at that "Dzehmukhskaya tselebnaya" medium-high mineralized thermal water with a standard content of biologically active boron 40-80 mg/dm3 in H3 BO3 acid and silicon 110-140 mg/dm3 in H2SiO3 acid and pH medium reaction of 6.5-7.0 is contained as the thermal water.EFFECT: cosmetic means has a tonic, moisturizing, softening and refreshing properties, it helps to eliminate disturbances in sebaceous glands secretion, skin texture.4 tbl
ethod for treatment of destructive chronic periodontitis using injection form of autological platelet plasma // 2627582
FIELD: medicine.SUBSTANCE: method includes instrumental processing using rotor instruments with an extension of the apical part of the channel to a diameter of at least 025 ar per ISO, conicity of at least 4%, drug treatment of the dental canals with passive ultrasonic irrigation and canal drying, temporary obturation of canals with calcium hydroxide with sealing under glass ionomer cement, general drug therapy. Drug treatment is carried out with a 17% solution of ethylenediaminetetraacetate and 1.5% sodium hypochlorite solution, after 12-24 hours after calcium hydroxide repfreshing, injections of platelet autoplasma (PAP) are made into soft tissues in the fistula area, if present, submucosally in the transitional fold, subperiosteally in the projection of the apexes involved in the pathological process of roots from the vestibular or palatal, lingual surfaces. At that, calcium hydroxide refreshing and PAP injection the root canals are carried out once or 2-3 times with an interval of 7-10 days, then canal obturation is effected by lateral or vertical condensation of gutta-percha and the epoxide-amine resin-based sealer.EFFECT: use of the invention provides relief of acute inflammatory process, reduction of treatment time, stimulation of bone tissue regeneration and replacement of a defect in a chronic inflammation focus by accelerating natural mechanisms of tissue regeneration due to platelet-derived growth factors.6 dwg, 2 ex
ethod for atrophic skin scars treatment // 2627468
FIELD: medicine.SUBSTANCE: fully straightened filtered radio waves of high frequency, obtained by the radio wave device Surgitron®, and an autologous platelet-rich plasma are used. At that, blood is taken from the peripheral vein of the patient into vacuum tubes. Blood is mixed with an anticoagulant. The blood mixture is then centrifuged with an anticoagulant for 4-6 minutes at a centrifuge rotation speed of 700-900 rpm. After that, the upper layer of the platelet-rich plasma is extracted into a separate tube and activated by calcium ions by addition of calcium gluconate. The activated platelet-rich plasma is placed into the syringe and injected intradermally into the scar. The injected region is then warmed up to 41-43°C by the Surgitron® radio wave device with Pelleve® ClideSafe electrodes or PelleFirm for at least 4 minutes.EFFECT: invention allows to shorten the time of scars treatment in patients.11 cl, 1 ex

ethod for arachidonic acid production // 2627273
FIELD: pharmacology.SUBSTANCE: method for preparation of arachidonic acid from an animal raw material includes alkaline hydrolysis of lipids isolated from the raw material, followed by hydrolyzate acidification, iodine-lactonization reaction, iodine-lactone extraction from the reaction mixture with an organic solvent, iodine-lactone dilution with a silicone agent, neutralisation of the released iodine with sodium thiosulfate, fatty acids extraction with an organic solvent, where, prior to the iodine-lactonization reaction, lipid hydrolyzate is treated with lithium alkali in acetone and saturated acids are isolated as a precipitate, Iodine-lactonization is carried out by transferring lithium salts of unsaturated fatty acids to sodium salts, which are treated with iodine solution to form iodine-lactones of fatty acids at a ratio of the acids sum (arachidonic, eicosapentaenoic and docosahexaenoic):iodine equal to 1.0:1.0-1.2 mol/mol, at mixture temperature of 18-22°C, with duration of iodine solution addition to the reaction mixture of 30-60 minutes, followed by solutions maintaining for 60 minutes; after iodine-lactones extraction from the reaction mixture with an organic solvent, delta- and gamma-iodo-lactone separation is further carried out by chromatography on silica gel using benzene as the eluent; and the disclosure of delta-iodine-lactones of arachidonic and eicosapentaenoic acids is carried out with silicide at a ratio of arachidonic acid iodine-lactone + eicosapentaenoic acid/silicide = 1.0:1.0-1.2 mol/mol, mixture temperature of 18-22°C, reaction time of 120-180 minutes; after fatty acids extraction with an organic solvent, they are esterified with ethyl alcohol and arachidonic acid is isolated as ethyl ether by reverse phase high performance liquid chromatography (C-18) using an ethanol-water eluting system of 8.0:1.0-2.5 vol./vol.EFFECT: easy and reproducible way to separate pure arachidonic acid from animal tissues, available for sale in laboratories and industrial plants using arachidonic acid in biochemical, medical and dietetic studies.4 cl, 2 dwg, 1 tbl, 5 ex

Aneurinibacillus migulanus strain and its application for gramicidin s production // 2627182
FIELD: biotechnology.SUBSTANCE: invention can be used to produce gramicidin S using the strain of the Aneurinibacillus migulanus VKPMV-10212 producer.EFFECT: resulting strain allows production of gramicidin S in high yield.2 cl, 2 dwg, 2 ex

Bacterium strains lactobacillus rhamnosus, with a wide spectrum of antagonistic activity relating to pathogenic and conditionally pathogenic microorganisms // 2627166
FIELD: biotechnology.SUBSTANCE: strain of bacteria Lactobacillus rhamnoses 24 ds, which has antagonistic activity against pathogenic and opportunistic microorganisms, including against yeast fungi of the genus Candida, deposited in the All-Russian Collection of Industrial Microorganisms under the registration number VKPM V-12596 and can be used In the production of probiotic bacterial preparations, biologically active food additives, fermented and unfermented food products.EFFECT: improved strain properties.1 dwg, 7 tbl, 2 ex

Bacterium strains lactobacillus rhamnosus 7 ds, with a wide spectrum of antagonistic activity relating to pathogenic and conditionally pathogenic microorganisms // 2627165
FIELD: biotechnology.SUBSTANCE: strain of bacteria Lactobacillus rhamnosus 7ds, which has antagonistic activity against pathogenic and opportunistic microorganisms, including those with yeast fungi of the genus Candida, was deposited in the All-Russian Collection of Industrial Microorganisms under the registration number VKPM V-12598. The strain can be used in the production of probiotic bacterial preparations, dietary supplements, fermented and unfermented foods.EFFECT: improved strain properties.1 dwg, 7 tbl, 2 ex

Bacterium strains lactobacillus rhamnosus, with a wide spectrum of antagonistic activity relating to pathogenic and conditionally pathogenic microorganisms // 2627164
FIELD: biotechnology.SUBSTANCE: strain of bacteria Lactobacillus rhamnoses 1 ds, which has antagonistic activity against pathogenic and opportunistic microorganisms, including against yeast fungi of the genus Candida, deposited in the All-Russian Collection of Industrial Microorganisms under the registration number VKPM V-12597 and can be used in the production of probiotic bacterial preparations, biologically active food additives, fermented and unfermented food products.EFFECT: improved strain properties.1 dwg, 7 tbl, 2 ex
ethod of treatment of central scrolleromy // 2627153
FIELD: medicine.SUBSTANCE: for the treatment of focal scleroderma, lesions are affected by low-energy laser radiation of the infrared range with a repetition rate of 1500 Hz, a pulse duration of 110-160 ns, a pulse power of 4-6 W/pulse, and 1-3 minutes per field. The total duration of exposure is no more than 15 minutes. Immediately before exposure to laser radiation on the scleroderma foci impose a gel for the body NOLLA naturelle®. In this case, exposure to laser radiation alternates every other day with paraffin applications on scleroderma foci, at a temperature of 48-52°C, time 20 minutes. The course of treatment is 8-10 complex procedures.EFFECT: method provides a multifactorial effect on all parts of metabolic processes in pathologically altered fibrotic dermal foci with a reduction in side effects and contraindications to the treatment.2 ex
ethod for hypertrophic gingivitis treatment in patients with non-removable orthodontic devices with application of injection form of autological platelet-rich plasma // 2626826
FIELD: medicine.SUBSTANCE: for conservative treatment of hypertrophic gingivitis in patients with non-removable orthodontic devices against the background of professional oral hygiene and topical application of chlorhexidine within 10 days, fraction of platelet-rich autologous plasma obtained from the supernatant space of tube after centrifugation is injected intrapapillary into the hypertrophic gingiva papillae, and the remaining fraction is introduced submucosally into the transitional fold in a total volume of 8-9 ml in the area of all teeth. The injection procedure is repeated after 7 days.EFFECT: method allows to shorten the treatment time, to stop the inflammatory process, to stimulate regeneration due to acceleration of its natural mechanisms due to the growth factors contained in platelets in the prevention of relapse.5 dwg, 1 tbl, 2 ex
ethod for prevention of periodontium inflammatory diseases in patients with non-removable orthodontic devices with application of injection form of autological platelet-rich plasma // 2626825
FIELD: medicine.SUBSTANCE: for prevention of inflammatory periodontal diseases in patients on orthodontic treatment with non-removable devices after the hardware professional oral cavity hygiene with local use of chlorhexidine for 7 days, autologous platelet plasma is injected submucosally into the transitional fold in a total volume of 8-9 ml in the region of all teeth. The procedure is repeated in the framework of supporting periodontal therapy at intervals of 4-6 months during orthodontic treatment and once in the retention period.EFFECT: method allows to prevent inflammatory complications from the periodontal tissues due to the acceleration of the natural tissue regeneration mechanisms.4 dwg, 1 tbl, 1 ex
ethod of treatment of posttraummatic fibrosive ankiloses of small juices of brush // 2626591
FIELD: medicine.SUBSTANCE: method includes the installation of an external fixation device (EFD) and the implementation of a stage distraction of the joint area up to 9 mm by 3 mm per day. In the formed cavity on the 3rd and 6th day after the AVF installation, 1.5-2 ml of plasma enriched with platelets (PRP) is injected, which amounts to 1,000,000-1200,000 cells. After the second injection, the EFD is dismantled and active rehabilitation treatment is carried out. The third injection of PRP is performed pararticularly on the 9th day.EFFECT: reducing the time to restore or improve the function of the fingers.1 ex, 5 dwg
Therapeutic application of krill oil // 2625760
FIELD: medicine.SUBSTANCE: proposed: method for endotoxemia treatment by parenteral administration of a krill oil composition containing phospholipids derived from krill, in an oil-in-water emulsion for injection, wherein triglycerides comprise at least 60% of omega-3 fatty acids based on the total weight of fish oil triglyceride fatty acids; application of the said composition for the same purpose; method for high-lipophilic drugs excessive doses toxicity neutralisation or drugs harmful effects reduction, comprising parenteral administering of the said composition; use of krill oil containing phospholipids derived from krill as an emulsifier in an oil-in-water emulsion in the composition for injection, and its use for endotoxemia treatment during sepsis.EFFECT: stability and safety of claimed compositions for intravenous administration.5 cl, 9 tbl

ethod of production of antiseptic dorogov's stimulator (ads) nanocapsules fraction 2 in carrageenan // 2625547
FIELD: nanotechnology.SUBSTANCE: invention relates to a method of production of antiseptic Dorogov's stimulator (ADS) nanocapsules 2 fraction in carrageenan. This method is characterized in that the ASD 2 fraction is dispersed in a solution of carrageenan in benzene in the presence of E472c preparation as a surfactant in stirring at 1,300 rpm, then 10 ml of sulphuric ether are added, the resulting suspension is filtered off and dried at room temperature. The mass ratio core: shell is 1:1, 1:3 or 3:1.EFFECT: simplification and acceleration of the process of producing the nanocapsules, as well as increase in their yield by weight.3 dwg, 4 ex
ethod for calves growing in arvi-hazardous economics // 2625022
FIELD: veterinary medicine.SUBSTANCE: method includes biostimulator introduction prior to vaccination, which is a complex preparation based on the ASD-2 fraction, the therapeutic solution of the preparation being prepared with 0.9% isotonic sodium chloride solution, and a liquid form of "Vivaton", kept for 36-48 hours in an open bowl under a hood until the smell of ammonia completely disappears, and injection aloe are added as a supplement. The finished form of the complex biostimulator preparation contains, wt %: ASD-2 fraction - 4; "Vivaton" - 10; injection aloe - 6; 0.9% isotonic sodium chloride solution - the rest. Normothrophic calves receive the preparation twice at a dose of 0.025 ml per 1 kg of live weight 24 hours prior to vaccine introduction and on the day of vaccination, and hypotrophic calves - twice, 5-10 days prior to vaccination.EFFECT: invention allows to obtain a preparation with a wide spectrum of action, which makes it possible to increase the effectiveness of calves ARVI treatment, and can be used both in large livestock complexes and farms, as well as on personal farms.2 cl, 6 tbl
ethod for adhesiogenesis stimulation in pleural cavity in case of polytraumas with predominant thoracic involvement // 2625002
FIELD: medicine.SUBSTANCE: invention concerns adhesionogenesis stimulation in the pleural cavity in case of polytraumas with predominant thoracic involvement. To do this, a 10% homogenized suspension of autologous adipose tissue in a physiological solution is injected pointwise into the pleural cavity into the ribs fracture region subpleurally, under the parietal pleura.EFFECT: method ensures pulmonary framework stabilisation and early fusion of ribs due to adhesiogenesis stimulation and adhesions formation in the pleural cavity.2 cl, 1 ex
Preparation method of the complex gel for mastitis treatment and prevention in cows and complex gel on its basis // 2624868
FIELD: veterinary medicine.SUBSTANCE: complex gel contains antimicrobial and anti-inflammatory drugs. As the antimicrobial drugs it contains metronidazole, chlorhexidine bigluconate 0.05%, tea fungus culture biomass. As the anti-inflammatory drugs it contains the plant components extracts: mother coltsfoot, chamomile pharmacy, birch buds, celandine, nettle, horseradish and chlorophytum, wherein the propylene glycol is used in the ratio of 1:5 as the extracting agent, additionally include the acrylic acid and triethanolamine in the following ratio, g/l: chlorhexidine digluconate 0.05% 9-13, metronidazole 3.5-5.0, acrylic acid 2.5-3.5, triethanolamine 1.0-1.5, mother coltsfoot extract 1.0-1.5, chlorophytum extract 1.0-1.5, chamomile pharmacy 1.0-1.5, birch buds extract 1.0-1.5, celandine extract 1.0-1.5, nettle extract 1.0-1.5, horseradish extract 1.0-1.5, tea fungus culture biomass - the rest. The claimed method of the complex gel preparation for the treatment and prevention of mastitis in cows concludes in mixing of antimicrobial and anti-inflammatory drugs, homogenization. The plant components are pre-dried, then in the amount of 1-1.5 g each it is homogenized and poured with the extractant. Propylene glycol is used as the extractant in the ratio of 1:5. It is additionally infused for 14-15 days and filtered. Prepare the tea fungus culture biomass, then infused for 10-12 days, then homogenize with the zoogloea of the tea fungus, dilute it with the infusion of tea fungus in the ratio of 1.6:1, respectively, until the homogeneous gel mass is obtained. Digest for 10-12 minutes, with further step by step addition of all components into the mixer, homogenization until the homogeneous gel mass is obtained and packed into the sterile syringes.EFFECT: claimed group of inventions application is highly effective for the mastitis treatment and prevention in cows.2 cl, 5 tbl, 9 ex
ethod for complex treatment of patients with inflammatory periodontal diseases // 2624867
FIELD: medicine.SUBSTANCE: antiseptic treatment of the oral cavity is performed. Then, dental deposits are removed ultrasonically and manually. After that, a periodontal bandage is applied to the gum area of the upper and lower jaws, containing metronidazole, anesthesin and larva extract of large wax moth as active ingredients, and dimethicone 1000, styrene-maleic anhydride copolymer, T-2 emulsifier, vaseline oil, Lutrol F-68, Kollidon CL-M, orange essential oil as an ointment basis and purified water at a certain ratio of components. The course of treatment for patients with gingivitis and light chronic generalized periodontitis (CGP) is 3 sessions, with medium CGP - 5 sessions, severe CGP - 7 sessions, conducted every other day. Additionally, the gingival margin is treated 2 times a day with a dental pencil. The pencil contains metronidazole, baktisubtil and 10% alcohol extract of large wax moth larvae and auxiliary substances: beeswax, emulsifier No. 1, methylparaben, paraffin, peach oil, low molecular weight polyethylene with a molecular weight of 500-5000, lutrol F-127 and cremophor RN-40.EFFECT: increased therapeutic effect due to regenerative, immunomodulating, anesthetic, antibacterial and antiviral action of complex drugs used.2 tbl, 4 ex
eans with diuretic activity // 2624851
FIELD: pharmacology.SUBSTANCE: invention is a diuretic agent containing a 0.5% solution of fulvic acids in an amount of 40 ml and manganese oxide in an amount of 0.1 g.EFFECT: invention allows to increase the therapeutic effect and to exclude occurrence of side effects.2 ex
Way to prevent viral diseases of birds // 2624503
FIELD: veterinary medicine.SUBSTANCE: way includes the injection of transfer-factor to the bird. Transfer factor is obtained from blood leukocytes vaccinated against one or more infections or outgrown their chickens or chickens. The drug is injected to the poultry of all ages aerosol melkodispersno one dose on the head upon exposure of 20-25 minutes. Aerosol producing distilled water with the addition of 10% glycerol to the volume.EFFECT: use of the claimed invention is highly effective for the prevention of infectious disease in birds and improve preventive vaccines.4 cl, 2 tbl, 3 ex
ethod for preparation and application of autological erythrocytes from umbilical blood for anemia correction in newborns // 2624253
FIELD: medicine.SUBSTANCE: method includes the following steps: umbilical cord samples collection, processing, placement for storage and rejection of samples, a pre-transfusion processing for umbilical blood samples. At the pretransfusion preparation stage, the erythrocyte mass from the plasma is separated by centrifugation at acceleration of 3768 g for 15 minutes at a temperature of +4°C. Then the auto-erythromass samples pass the procedure of auto-erythrocytes washing from the preservative and hemolyzed cells formed during umbilical cord sample storage. To do this, 100 ml of sterile physiological sodium chloride solution is added to the packet with auto-erythromass in the umbilical erythromass and physiological solution ratio of 1:1 and centrifuged at 1971 g acceleration for 10 minutes at a temperature of +4°. After this, the supernatant is removed using a plasma extractor. The washed umbilical erythrocytes are filtered through a microaggregate filter. All samples of autologous erythrocytes of umbilical blood pass quality control: the degree of hemolysis and quantitative indicators of blood cells, hemoglobin and hematocrit are determined.EFFECT: invention allows to correct anemia in newborns by a single blood transfusion, without occurrence of posttransfusion complications associated with donor blood components transfusion.11 tbl, 3 ex

Composition for use during angiogenesis augmentation in intestine, nutrient absorption and tolerance to enteral nutrition, and/or during prevention and/or treatment of inflammatory intestine diseases, and/or during recovery from intestine injury and surgical intervention // 2624233
FIELD: pharmacology.SUBSTANCE: composition comprising at least one longchain polyunsaturated fatty acid (LC-PUFA), at least one probiotic and a mixture of oligosaccharides comprising at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide for angiogenesis augmentation in intestine and nutrient absorption, tolerance to enteral nutrition of suckling children or growing infants; its use as a synthetic nutrient agent for the same purpose; composition of the same formulation used during prevention and/or treatment of inflammatory intestine diseases, representing necrotizing enterocolitis, and/or during recovery from injury and/or surgical intervention in the intestine area of suckling children or growing infants, and its use as a synthetic nutrient agent for the same purpose are proposed.EFFECT: angiogenesis augmentation in intestine, which enables to reduce the risk of necrotizing enterocolitis and facilitates recovery from injury or surgical intervention in intestine of suckling children or growing infants.26 cl, 4 dwg, 4 tbl
ethod for treatment of patients with acute stage of diabetic neurosteoartropathy of charcot foot type // 2624230
FIELD: medicine.SUBSTANCE: invention relates to treatment of the acute stage of diabetic neuro-osteoarthropathy ("Charcot foot"). To do this, the affected limb is unloaded and 2.0 to 4.0 ml of platelet-enriched autoplasma is injected into the area of aseptic inflammation and osteodestruction. The number of procedures is from 1 to 3 per a course of treatment of up to 2-3 weeks.EFFECT: method prevents the development of destruction of the foot osteoarticular apparatus, deformation and plantar ulcer defects formation.1 ex
Probiotic bacterial strain (versions) and symbiotic composition containing strains for child nutrition // 2624043
FIELD: biotechnology.SUBSTANCE: strain of Bifidobacterium breve B2274 DSM 24707, Bifidobacterium breve B7840 DSM 24708 and Bifidobacterium longum subsp.longum B1975 DSM 24709 bacteria possessing antimicrobial activity against pathogens of E. coli, Salmonella enteriditis, Clostridium difficile and Campylobacter jejunii was proposed. A pharmaceutical composition having antimicrobial activity against E. coli, Salmonella enteriditis, Clostridium difficile and Campylobacter jejunii pathogens and containing a bacterial mixture is also provided. The said bacterial mixture comprises at least one bacterial strain selected from the group consisting of Bifidobacterium breve B632 DSM 24706, Bifidobacterium breve B2274 DSM 24707, Bifidobacterium breve B7840, DSM 24708 and Bifidobacterium longum subsp. longum B1975 DSM 24709. A food composition and a food additive containing the bacterial mixture are also provided. The bacterial mixture contains at least one bacterial strain selected from Bifidobacterium breve B2274 DSM 24707, Bifidobacterium breve B7840 DSM 24708 and Bifidobacterium longum subsp. longum B1975 DSM 24709.EFFECT: increased antimicrobial activity of the strain.14 cl, 5 dwg, 2 tbl

Bacterial strain, capable of oxalate metabolism // 2624033
FIELD: biotechnology.SUBSTANCE: strain of Lactobacillus paracasei spp. Paracasei LPC 09 DSM 24243 bacteria is proposed, which decomposes oxalic acid and/or its salts. The use of a pharmaceutical composition for prevention or therapeutic treatment of hyperoxaluria, urolithiasis, renal failure, cardiopathies, kidney stones, diverticulosis and diverticulitis is proposed. At that, the pharmaceutical composition comprises a bacterial composition comprising a plurality of cells of at least one bacterial strain, wherein at least one bacterial strain is Lactobacillus paracasei spp. paracasei LPC 09 DSM 24243. A food composition comprising a bacterial composition comprising a plurality of cells of at least one bacterial strain, wherein at least one bacterial strain is Lactobacillus paracasei spp. paracasei LPC 09 DSM 24243 is also provided.EFFECT: effective decomposition of oxalic acid or its salt in an amount of more than 60 percent.10 cl, 5 dwg, 2 tbl
ethod for treatment of glaucomous optic neuropathy by means of transplantation of 3d cellular culture of multipotent mesenchimal scleral sulcus stem cells // 2623646
FIELD: medicine.SUBSTANCE: method involves application of multipotent mesenchymal stem cells (MMSC), obtained from allogeneic fragments of the human cadaver eyes scleral sulcus. 3D cell spheroids, 1000 cells in each spheroid, are created from these cells. 250 to 500 spheroids in 1 ml of a sterile 0.9% solution of sodium chloride are administered once parabulbarically.EFFECT: method allows to improve and stabilise visual functions, to provide anti-apoptotic action, to prevent involvement of intact ganglion retinal cells in the apoptosis process due to a prolonged and stable secretion of neurotrophic factors by 3D-cell spheroids of multipotent mesenchymal stem cells.2 ex
ethod for industrial manufacture of mineral healing and drinking hydrocarbonate magnesium-calcium iron marcial water // 2623155
FIELD: pharmacology.SUBSTANCE: mineral water is taken from the source, then stabilized with chelate compounds with Fe2+, resulting from the addition of a mixture of 0.65 g of citric acid and 0.35 g of ascorbic acid per 1 liter of mineral water at Fe2+ content in the range of 45-60 mg/l or a mixture of 1.3 g of citric acid and 0.7 g of ascorbic acid per 1 liter of mineral water at Fe2+ content of more than 60 mg/l, then the mineral water is poured into vials, they are tightly closed and the sealed vials are treated with hot steam at a pressure of 0.8 atm for 30 minutes.EFFECT: ability to preserve the healing properties of water after extraction for a longer shelf life after bottling.2 dwg, 3 tbl
ethod for biologically active concentrate production from maral skin // 2623146
FIELD: pharmacology.SUBSTANCE: method for biologically active concentrate production from the maral skin, including skin is grinding to the state of minced meat and subjecting to enzymatic hydrolysis, followed by extraction by ultrasonic vibrations. Enzymatic hydrolysis is carried out in the presence of pepsin and papain enzymes, with enzyme pepsin being introduced into the process at the beginning of the extraction, and papain - in the middle of the time period of extraction, after filtration, the extract is dried under certain conditions.EFFECT: method allows to obtain biologically active concentrate from the maral skin and thereby expand the arsenal of maral breeding products.2 cl, 4 tbl, 1 ex
ethod of obtaining sex ferromons of pets // 2623085
FIELD: veterinary medicine.SUBSTANCE: way of obtaining sex pheromones of male pets includes grinding, homogenization of their testes, adding the enzyme protosubtilina, incubation, centrifugation, mixing with the urine and distillation with water vapour. While polysorbate TWIN-8 is added to the gomogenizat at the amount of 0.5-1.0% of the total mass. The mixture is then incubated for 50-60 min 37-39°C, mixed with the urine of males by a ratio of 1:3-3.5 and distilled with water vapour.EFFECT: enables the enhancement of the biological activity of the drug and increase its output.3 tbl, 3 ex
Antibacterial composition in form of suppository and method of its preparation // 2622762
FIELD: pharmacology.SUBSTANCE: invention is an antibacterial composition in the form of a suppository and a method of its preparation, wherein the composition comprises a liquid substance of bacteriophages containing at least three bacteriophages with a titre of at least 2⋅108 BFU per suppository of each strain, suppository base, including witepsol or tallow of type A, as well as Tween-80, wherein the composition components are in a certain ratio, in % per 1 suppository.EFFECT: systemic antibacterial effect and maintenance of initial high phage lysate titre.2 cl, 2 dwg, 7 tbl, 5 ex, 3 dwg
ethod for erectile dysfunction treatment // 2622757
FIELD: medicine.SUBSTANCE: fat tissue is taken from a patient under local anesthesia or intravenous anesthesia by liposuction in a volume of up to 250 ml. The fat tissue is processed on the Celution 800/CRS hardware complex for 1.5 hours and 4.0 ml of stromal-vascular fraction (SVF) is obtained. At that, the SWF contains 50 million or more cells. The SWF is then intracavernously administered to the patient at 6 points along the lateral surface of the penis bilaterally. 1.0 ml are administered proximally, 0.5 ml - medially and distally, total 2.0 ml per cavernous body. Then, a tightening garrot is put on the penis base for 15 minutes.EFFECT: increased effectiveness of treatment due to the absence of complications and side effects in patients with erectile dysfunction.2 ex
Based on bioresources compositions for prevention or treatment of sepsis and/or sepsis-related complications and conditions, methods for sepsis prevention and treatment // 2622745
FIELD: medicine.SUBSTANCE: invention relates to the field of medicine and deals with application of composition, containing hydrolysate, obtained by means of acidic and/or fermentative hydrolysis of one or more bioresources, selected from the group including bivalve molluscs, annelids, leeches; and water, for prevention or treatment of sepsis and/or sepsis-related complications and conditions in mammal requiring such treatment or prevention. Essence of the method consists in the following: composition, containing hydrolysate, obtained by means of acidic and/or fermentative hydrolysis of one or more bioresources, selected from the group including bivalve molluscs, annelids, leeches; and water is parenterally introduced to patient for 1-10 days in dose 10-400 mcl/h.EFFECT: application of the invention makes it possible to increase efficiency of sepsis treatment.30 cl, 7 tbl, 2 ex
ethod of treatment of mastitis in lactating cows // 2622017
FIELD: veterinary medicine.SUBSTANCE: method comprises intracisternal injecting of the drug at a dose of 10.0 ml to the affected udder part with 12-hourly intervals 2-4 times. Injectable preparation contains succinic acid, ph-2 ASD, iodine and potassium iodide, the polyvinyl alcohol and procaine at the following component ratio, wt %: Succinic acid 1.0, ASD ph-2 2.0, 0.1 iodine, potassium iodide 0.5, procaine 0.5 polyvinyl alcohol 1.0, purified water is the rest.EFFECT: invention is highly effective for the treatment of mastitis in lactating cows.2 tbl, 3 ex

Compositions based on clay and pollen, method for their obtaining and their application in nutrition and therapeutic treatment // 2622013
FIELD: pharmacology.SUBSTANCE: biologically active complex is obtained by mixing pollen with clay, taken in a specific proportion. The method for obtaining the complex. The pharmaceutical composition. The food composition. The gelatin capsule.EFFECT: group of solutions allows to obtain and to use a more stable form of pollen.11 cl, 6 dwg, 1 tbl, 4 ex
ethod for health procedures // 2621981
FIELD: medicine.SUBSTANCE: to conduct health-improving procedures in the maral breeding enterprise, patients are provided with a course of common baths with cooking pant water. The patients undergo preliminary thermal procedure at a temperature of 70-80°C in a factory hot oven for no more than 12 minutes. At that, the thermal procedure is started not earlier than 2 hours after reaching a temperature of 70-80°C within the oven. 4-6 minutes after the thermal procedure, common baths with cooking pant water are taken at a temperature of 38-40°C for 8-12 minutes. Baths are performed daily or once in two days with a course of no more than 10 procedures.EFFECT: increased efficiency of balneological influence with expanded spectrum of improving procedures.1 tbl, 1 ex
Amycolatopsis orientalis strain - producers of ehremomitcin antibiotic and method for ehremomitcin production // 2621866
FIELD: biotechnology.SUBSTANCE: Amycolatopsis orientalis strain, and a method for ehremomitcin antibiotic production are proposed. Amycolatopsis orientalis strain with high activity of ehremomitcin antibiotic production is deposited in the Russian National Collection of Microorganisms of the Institute of Biochemistry and Physiology of Microorganisms named after G.K. Skryabin, RAS under accession number VKMAc-2717D. Method for ehremomitcin antibiotic preparation includes antibiotic sorption from the culture fluid to the carboxyl cation exchanger Purolite C104 or C106 in H+-form, antibiotic elution by ammonia solution, eluate concentration, followed by neutralisation and crystallization as by precipitation by means of isopropanol.EFFECT: high product yield.2 cl, 2 tbl, 4 ex
Hematogen // 2621629
FIELD: food industry.SUBSTANCE: invention represents hematogen containing black food albumin, starch treacle, vanillin, whole condensed milk with sugar, granulated sugar, characterised in that it additionally contains fulvohumates, the components in the hematogen being in a certain ratio of ingredients in wt %.EFFECT: increasing the biological value of hematogen and digestibility of iron from food.
ethod for remote electromagnetic multiwave radio neuroengineering of human brain // 2621547
FIELD: medicine.SUBSTANCE: method for remote electromagnetic multiwave radio neuroengineering of human brain comprises the following steps: a) design and layout by complex diagnostic by means of brain MRI study, MRI tractography of brain damage zones (DZ) pathways, MRI angiography of brain vessels, brain positron emission tomography (PET) or whole body PET, brain computer tomography (CT), cerebral electroencephalographic mapping (EEG) and/or brain magnetoencephalography (MEG) to create individual 3D-map of nerve tissue (NT) damage simulation by a programmed multilevel merge of diagnostics data for subsequent determination of NT DZ by marking on the patient's head skin using a stereotactic radiotherapy and radiosurgery apparatus to determine tilt angles and effective radii of the subsequent non-ionizing stereotactic effect of focused ultrasound (FUS) on NT; b) NT DZ vascular bed resimulation using focused ultrasound under control of MRI ionizing radiation (IR) or structurally-resonance therapy (SRT); c) cell restoration of NT DZ by directed intervention of autologous mesenchymal stromal stem cells (MSSCs) mobilized in peripheral blood, hematopoietic stem cells (HSCs) and progenitor cells (PCs) into the NT DZ; d) NT DZ vegetative supply correction by means of combined exposure to electromagnetic non-ionizing radiation in the form of SRT with simultaneous or sequential exposure to FUS; e) dynamic integration of somatic and vegetative components by combining FUS exposure with simultaneous or subsequent SRT exposure; f) rehabilitation of damaged NT DZ functional state by combined application of SRT and FUS.EFFECT: method provides remote, non-invasive, focused, directed restoration of brain NT in treatment of a range of nervous and mental diseases at a stepwise combined exposure to different types of electromagnetic radiation, which eliminates disadvantages and complications from the use of these known methods of FUS, IR, SRT separately at minimum sufficient cellular intervention into the patient's brain.6 cl, 2 dwg, 7 tbl, 2 ex
ethod for obtaining proteoglycan // 2621311
FIELD: medicine; pharmacology.SUBSTANCE: urine is preliminarily cooled, kept until aggregates are formed, centrifuged to precipitate proteoglycan-free sediment, after that, precipitant, composition of which includes 4 volumes of 96° ethyl alcohol and 1 volume of 0.01 N solution of sodium hydroxide, is added to supernatant fluid in ratio 1:1 to precipitate proteoglycan, after which mixture is kept for 20 min without changing temperature to allow formation of aggregates, which are separated from supernatant fluid in mode of cooling at 0°C by centrifugation, sediment is washed by re-addition of cooled to 0°C precipitant in ratio 1:10, kept for 5 minutes until aggregates are formed, centrifuged again, supernatant fluid is separated, obtained sediment is dissolved by addition of 0.01 N of HCl solution, reducing pH value of final product to pH 7.2, remaining insufficient non-soluble sediment is separated by centrifugation, supernatant fluid, containing purified proteoglycan is used as intended.EFFECT: method, described above, provides obtaining highly-purified proteoglycan.3 cl, 6 dwg, 6 tbl, 3 ex
Pharmaceutical composition with antifungal action // 2621156
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition with antifungal activity, has the form of a cream containing anmarine, vaseline oil, triethanolamine, wax emulsion, isopropyl myristate, benzoic acid, taken at a certain component ratio.EFFECT: composition has an increased penetrating ability, which provides more effective and long-lasting antifungal action.1 tbl, 1 ex
ethod for dislipidemia prevention // 2621152
FIELD: medicine.SUBSTANCE: daily oral administration of "Maristim" and "Fukolam-S" food additives. "Fukolam-C" is administered 1 capsule once a day with meals, and "Maristim" 3 capsules 3 times a day after meals for 3-6 months. In this case, the first reception of "Maristim" is carried out 2 hours after of "Fukolam-C" reception.EFFECT: maximum lipid-regulating action and a decrease in the dose of statins in patients with dyslipidemia.1 tbl, 3 ex
Trichoderma asperellum strain - producer of hydrolytic enzymes and peptide metabolites and its application // 2620971
FIELD: biotechnology.SUBSTANCE: group of inventions refers to Trichoderma asperellum fungus strain VKPM F-1087 and its application as a promising drug for human antitumor cells activity suppression. Trichoderma asperellum strain VKPM F-1087 is a producer of hydrolytic enzymes and peptide metabolites possessing antibacterial, antitumor, fungicidal, enzymatic activities and can be used in biotechnology as well as in agriculture to inhibit phytopathogens.EFFECT: expanded spectrum of properties of the produced highly active strain metabolites.3 cl, ex 5